InvestorsHub Logo
Followers 10
Posts 343
Boards Moderated 0
Alias Born 10/28/2011

Re: None

Friday, 03/23/2012 1:03:13 PM

Friday, March 23, 2012 1:03:13 PM

Post# of 1302
BRACE YOURSELVES.......unless there is some larger "manipulator" puppetting the value and involved in this financing equation, with the volume fall-off now, there should reasonably be a price up-tick in response to fewer shares "for sale" by the holders.

Verisante is overdue and vastly undervalued at this point. Everyone, with few exceptions who has done significant research in this segment, is well aware. LOOK AT THE MARKET SEGMENT. When compared with the competition, having a 25x larger potential market for these devices, detecting not only melanoma but also the other 96% of skin cancers, consuming a fraction of the time 1 second vs. 2 minute scan time, and costing a fraction of the per-use-price for MD end-users $50 scan vs. $10/per disposable tip; Verisante brings only one word to mind.

SUPREMECY
only becomes more well established with each news release. further, with the current securities lawsuit faced by the nearest competitor in this sector, having two, not 1 but count 'em 2-securities attorneys at the helm for Verisante is no laughing matter unless, of course, you take stock in VRS-canada/VRSEF-usa/V3T-germany.

LOVING IT,
Walt